A Randomized Controlled Phase II Clinical Trial with Intradermal IMO-2125 (Tilsotolimod) in clinical cT3-4N0M0 Melanoma (Intrim 1 study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509461-20-00

Enrollment

214

Registered

2024-12-06

Start date

2020-01-22

Completion date

Unknown

Last updated

2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pT3-4 cN0M0 Melanoma

Brief summary

The rate of tumor positive SLN seven days after the experimental treatment.

Detailed description

Frequency and activation state of lymph node resident (LNR) conventional dendritic cells (DC) and melanoma antigen-specific T cell responses in the SLN and peripheral blood., RFS at 18 months, 24 months, 36 months, 5 years and 10 years after SNB., OS at 18 months, 24 months, 36 months, 5 5 years and 10 years after SNB.

Interventions

DRUGIMO-2125

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The rate of tumor positive SLN seven days after the experimental treatment.	—

Secondary

Measure	Time frame
Frequency and activation state of lymph node resident (LNR) conventional dendritic cells (DC) and melanoma antigen-specific T cell responses in the SLN and peripheral blood., RFS at 18 months, 24 months, 36 months, 5 years and 10 years after SNB., OS at 18 months, 24 months, 36 months, 5 5 years and 10 years after SNB.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026